22 completed, 3 unknown, 2 active not recruiting, 2 recruiting. 29 Phase 2, 6 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 22, Unknown 3, Active not recruiting 2, Recruiting 2 |
| Phase 3 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
Follow calcipotriene: new trials by email Literature Review of calcipotriene trials Research Report on calcipotriene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. Acupuncture, Calcipotriol 0.005% ointment, Chinese herb cream - Plaque Type Psorisis | Phase 2 | Recruiting | Mae Fah Luang University | 28 | 2026-02-09 | 2026-02-13 |
| Topical Calcipotriol Versus Photodynamic Therapy in the Treatment of Oral Leukoplakia Calcipotriol 0.005% gel, ALA mediated PDT - Oral Leukoplakia | Phase 2 / Phase 3 | Active not recruiting | Alexandria University | 30 | 2025-07-16 | 2026-06-22 |
| Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients Biopsy, Calcipotriene, Fluorouracil - Actinic Keratosis | Phase 2 | Active not recruiting | University of Arizona | 56 | 2024-07-02 | 2025-09-24 |
| Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss Topical minoxidil, Topical Vitamin D, Saline spray - Dermatology, Female Pattern Baldness | Phase 1 / Phase 2 | Unknown | Sohag University | 45 | 2023-05-20 | 2024-03-27 |
| 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream - Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ | Phase 2 / Phase 3 | Recruiting | Boston University | 200 | 2022-10-15 | 2025-11-28 |
| Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial Turmeric Extract, Turmeric Extract in Olive oil, Petrolatum - Psoriasis | Phase 2 / Phase 3 | Unknown | Zagazig University | 50 | 2019-09-01 | 2019-08-28 |
| Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene SNA-120, Placebo, Calcipotriene - Pruritus, Psoriasis | Phase 2 | Completed | Sienna Biopharmaceuticals | 73 | 2018-02-12 | 2019-02-08 |
| Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis HAT1, Calcipotriol - Psoriasis | Phase 2 | Completed | Haus Bioceuticals | 174 | 2016-02-29 | 2019-02-21 |
| Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test C-82 Topical Gel, Placebo, C-82 Topical Gel, 1%, Daivonex cream - Psoriasis | Phase 1 / Phase 2 | Completed | Prism Pharma Co., Ltd. | 14 | 2015-06-01 | 2017-08-17 |
| "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy" Calcipotriene, Placebo - Acne Vulgaris | Phase 2 / Phase 3 | Completed | University of California, Los Angeles | 66 | 2013-02-01 | 2019-05-07 |
| LEO 90100 in the Treatment of Psoriasis Vulgaris LEO 90100, Calcipotriol, Betamethasone - Psoriasis Vulgaris | Phase 2 | Completed | LEO Pharma | 303 | 2012-05-01 | 2025-03-07 |
| LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle - Psoriasis Vulgaris | Phase 2 | Completed | LEO Pharma | 376 | 2012-05-01 | 2025-03-07 |
| Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis HAT1 topical solution, Calcipotriol - Psoriasis, Psoriasis Vulgaris | Phase 1 / Phase 2 | Completed | Haus Bioceuticals | 28 | 2012-01-06 | 2017-03-03 |
| Nicotinamide in the Treatment of Psoriasis Calcipotriol plus Nicotinamide, Calcipotriol - Psoriasis | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 66 | 2011-07-01 | 2013-01-08 |
| Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients M518101, placebo, Dovonex - Plaque Psoriasis | Phase 2 | Completed | Maruho Co., Ltd. | 294 | 2011-02-01 | 2015-11-05 |
| Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis Indigo Naturalis Extract in Oil, Calcipotriol Solution - Nail Psoriasis | Phase 2 / Phase 3 | Completed | Yin-ku Lin | 33 | 2011-01-01 | 2019-09-10 |
| A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris 0.03% E6201, 0.1% E6201, 0.2% E6201 - Psoriasis Vulgaris | Phase 2 | Completed | Eisai Limited | 30 | 2010-03-15 | 2021-06-11 |
| Safety and Efficacy of BFH772 in Psoriasis Patients BFH772, Placebo, calcipotriol/betamethasone - Psoriasis, Arthritis | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 15 | 2009-09-01 | 2011-03-28 |
| Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris Calcipotriene plus betamethasone dipropionate ointment - Psoriasis Vulgaris | Phase 2 | Completed | LEO Pharma | 33 | 2009-07-01 | 2025-03-12 |
| A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis CRx-197, Nortriptyline, Calcipotriol - Plaque Psoriasis | Phase 2 | Completed | Zalicus | 20 | 2008-11-01 | 2009-01-15 |
Showing 20 of 29. Sign in to see all of them.
Psoriasis (10) · Pruritus (2) · Acne Vulgaris (1) · Alopecia (1) · Arthritis (1) · Breast Neoplasms (1) · Dermatitis, Atopic (1) · Erythema (1) · Keratosis, Actinic (1) · Leukoplakia, Oral (1) · Neoplasms (1) · Radiodermatitis (1) · Squamous Intraepithelial Lesions (1)
LEO Pharma (8) · Haus Bioceuticals (2) · Alexandria University (1) · Boston University (1) · Deltanoid Pharmaceuticals (1) · Eisai Limited (1) · ISDIN (1) · Isfahan University of Medical Sciences (1) · Mae Fah Luang University (1) · Maruho Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Prism Pharma Co., Ltd. (1) · Rabin Medical Center (1) · Sienna Biopharmaceuticals (1) · Sohag University (1)
United States (11) · Germany (7) · Canada (5) · United Kingdom (4) · Egypt (2) · Denmark (1) · Finland (1) · Iran (1) · Ireland (1) · Israel (1) · Sweden (1) · Taiwan (1) · Thailand (1)
Amy S Paller, MD (1) · Bilal Fawaz, MD (1) · Colin Fleming, MD (1) · Eglal M Moussa, PhD oral medicine (1) · Elisabeth Theis, MD (1) · Essam A Nada, MD (1) · Eyal Fenig, M.D. (1) · Hagar Nofal (1) · Jenny Kim, MD,PhD (1) · Johannes Gassmueller, MD (1) · John Koo, MD (1) · Joseph Mercer (1) · Kristian Thestrup-Pedersen, MD (1) · Mark Lebwohl, M.D. (1)
PMID 25738921, PMID 32785881, PMID 34397196
2009 (1), P30CA023074 (1), R01AR053542 (1), UG1CA242596 (1)